Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for GLUCAGEN
- Pancreatic Clamp in NAFLD
- A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System
- Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
- Metabolic Adaptation to High-frequent Hypoglycaemia in Type 1 Diabetes
- Low-dose Glucagon for Prevention of Exercise-Induced Hypoglycemia in People With Type 1 Diabetes
- Dual-Hormone Closed-Loop Glucose Control in Adolescents With Type 1 Diabetes
- Dual-hormone Closed-loop Glucose Control in Type 1 Diabetes
- G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes
- Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children
- Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition
- Hepatic Metabolic Changes in Response to Glucagon Infusion
- First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.
- A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects
- A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus
- A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus
- A Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With T1DM
- In Vivo Assessment of Cellular Metabolism in Humans
- Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon
- Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons
- Bioequivalence of Fresenius Kabi USA, LLC Glucagon for SC Injection Compared to Glucagon for Injection (Bedford Laboratories)
- PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients
- A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)
- Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
- Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
- Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver
- Physiologic Response to Glucagon at Varying Insulin Levels
- Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET
- Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone
- The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET
- Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers
Clinical trials list
click for details